Cervical Carcinoma clinical trials

Explore recruiting cervical carcinoma clinical trials.

Recruiting cervical carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cervical Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase II study of Cemiplimab before and after standard chemoradiotherapy for patients with locally advanced cervical carcinoma. CADILLACC TRIAL

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma

Germany, Netherlands, France, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

CAT-01

Sweden

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Pilot Study on Subcutaneously Administered Immunotherapy for the Treatment of Cervical Cancer

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial,Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma.

Spain, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

France, Germany, Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Cervical Carcinoma trials by city

Cervical Carcinoma in Toronto Cervical Carcinoma in Vancouver Cervical Carcinoma in Montreal Cervical Carcinoma in Calgary Cervical Carcinoma in Edmonton Cervical Carcinoma in Ottawa Cervical Carcinoma in Winnipeg Cervical Carcinoma in Quebec City Cervical Carcinoma in Hamilton Cervical Carcinoma in Kitchener Cervical Carcinoma in London Cervical Carcinoma in Halifax Cervical Carcinoma in New York Cervical Carcinoma in Los Angeles Cervical Carcinoma in Chicago Cervical Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease